Molecular pathology of malignant melanoma

American Journal of Clinical Pathology

Volumn 110, Issue 6, 1998, Pages 788-794

  Slominski, Andrzej ^a   Wortsman, Jacobo ^b   Nickoloff, Brian ^a   McClatchey, Kenneth ^a   Mihm, Martin C ^c   Ross, Jeffrey S ^d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Melanoma; Melanoma markers; Molecular biology; Pathology; Progression

Indexed keywords

BIOCHEMICAL MARKER; CYTOKINE RECEPTOR; GROWTH FACTOR;

CYTOGENETICS; DNA DETERMINATION; HISTOPATHOLOGY; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; TISSUE DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 0031772320     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/110.6.788     Document Type: Review

References (136)

1. Slominski A, Ross J, Mihm M. Cutaneous melanoma: pathology, relevant prognostic indicators and progression. Br Med Bull. 1995;51:548-569.
2. Lejeune FJ, Chaudhuri PK, Das Gupta TK, eds. Malignant Melanoma: Medical and Surgical Management. New York, NY: McGraw-Hill; 1994.
3. Balch CM, Houghton AN, Milton GW, et al, eds. Cutaneous Melanoma. Philadelphia, Pa: Lippincott; 1992.
4. Gilbert SF, ed. Developmental Biology. Sunderland, Mass: Sinauer; 1988.
5. Slominski A, Paus R, Schanderdorf D. Melanocytes as sensory and regulatory cells in the epidermis. J Theor Biol. 1993;164:103-120.
6. Slominski A, Paus R. Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J Invest Dermatol 1993;101:90S-907S.
7. Halaban R, Kwon BS, Ghosh S, et al. bFGF as an autocrine growth factor for human melanomas. Oncogene Res. 1988;3:177-186.
8. Halaban R. Growth factors and tyrosine protein kinases in normal and malignant melanocytes. Cancer Metastasis Rev. 1991;10:129-140.
9. Halaban R, Rubin JS, Funasaka Y, et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene. 1992;7:2195-2206.
10. Herlyn M, ed. Molecular and Cellular Biology of Melanoma. Austin, Tex: RG Landes; 1993.
11. Yaar M, Gilchrest B. Human melanocyte growth and differentiation: a decade of new data. J Invest Dermatol. 1991;97:611-617.
12. Weterman MAJ, Van Muije GNP, Bloemers HPJ, et al. Biology of disease: molecular markers of melanocytic tumor progression. Lab Invest. 1994;70:593-608.
13. Thody AJ. Epidermal melanocytes: their regulation and role in skin pigmentation. Eur J Dermatol. 1995;5:558-565.
14. Imokawa G, Yada Y, Kimura M. Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochem J. 1996;314:305-312.
15. Krasagakis K, Garbe C, Orfanos CE. Cytokines in human melanoma cells: synthesis, autocrine stimulation and regulatory functions: an overview. Melanoma Res. 1993;3:425-433.
16. Slominski A, Paus R, Wortsman J. On the potential role of proopiomelanocortin in skin physiology and pathology. Mol Cell Endocrinol. 1993;93:C1-C6.
17. Kerbel RS. Expression of multi-cytokine resistance and multigrowth factor independence in advanced stage of metastatic cancer. Am J Pathol. 1992;141:519-524.
18. Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 1996;56:2191-2198.
19. Dummer W, Bastian BC, Ernst N, et al. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer. 1996;66:607-610.
20. Lattime EC, Mastrangelo MJ, Bagasra O, et al. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother. 1995;41:151-156.
21. Kerbel RS, Kobayashi H, Graham CH, et al. Analysis and significance of the malignant "eclipse" during the progression of primary cutaneous human melanomas. J Invest Dermatol Symp Proc. 1996;1:183-187.
22. Scott G, Stoler M, Sarkar S, et al. Localization of basic fibroblast growth factor mRNA in melanocytic lesions by in situ hybridization. J Invest Dermatol. 1991;96:318-322.
23. Kahn R, Murray M, Pawelek J. Inhibition of proliferation of Cloudman S91 melanoma cells by insulin and characterization of some insulin-resistant variants. J Cell Physiol. 1980;103:109-119.
24. Bregman MD, Abdel Malek ZA, Meykens FL. Anchorage-independent growth of murine melanoma in serum-less media is dependent on insulin or melanocyte-stimulating hormone. Exp Cell Res. 1985;157:419-428.
25. Slominski A, McNeely T, Pawelek J. Insulin receptor proteolysis in insulin resistant variants of Cloudman S91 melanoma cells. Melanoma Res. 1992;2:115-122.
26. Pawelek J, Murray M, Fleischmann. Genetic studies of insulin action in Cloudman melanoma cells. Cold Spring Harbor Conf Cell Prolif. 1982;9:911-919.
27. Fleischmann RD, Pawelek JM. Evidence that a 90-kDa phosphoprotein, an associated kinase, and a specific phosphatase are involved in the regulation of Cloudman melanoma cell proliferation by insulin. Proc Natl Acad Sci U S A. 1985;82:1007-1011.
28. McNeely T, Slominski A, Bomirski A, et al. Phosphorylation of protein of approximately 90 K daltons is a factor in the regulation of melanoma cell growth by insulin and the expression of high affinity receptors for insulin. In: Puet D, ed. Advances in Gene Technology: Molecular Biology of the Endocrine System. ICSU Short Reports. Cambridge Mass: Cambridge University Press; 1986:4:55.
29. Elder DE, Rodeck U, Thurin J, et al. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res. 1989:49:5091-5096.
30. Carrel S, Dore JF, Ruiter DJ, et al. The EORTC melanoma group exchange program: evaluation of a multicenter monoclonal antibody study. Int J Cancer. 1991;48:836-847.
31. Ellis DL, King LE, Nanney LB. Increased epidermal growth factor receptors in melanocytic lesions. J Am Acad Dermatol. 1992;27:539-546.
32. Nanney LB, Coffey RJ, Ellis DL. Expression and distribution of transforming growth factor-α within melanocytic lesions. J Invest Dermatol. 1994;103:707-714.
33. Reed JA, McNutt NS, Prieto VG, et al. Expression of transforming growth factor-β2 in malignant melanoma correlates with the depth of tumor invasion. Am J Pathol. 1994;145:97-104.
34. Schmid P, Itin P, Rufli T. In situ analysis of transforming growth factors-βs (TGF-β1, TGF-β2, TGF-β3), and TGF-β type II receptor expression in malignant melanoma. Carcinogenesis. 1995;16:1499-1503.
35. Van Belle P, Rodeck U, Nuamah I, et al. Melanoma-associated expression of transforming growth factor-β isoforms. Am J Pathol. 1996;148:1887-1894.
36. Fleming MG, Howe SF, Graf LH. Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas. Am J Dermatopathol. 1994;16:383-391.
37. Dos F, Chi DDJ, Charuworn BB, et al. Detection of β-human chorionic gonadotropin mRN A as a marker for cutaneous malignant melanoma. Int J Cancer. 1996;65:454-459.
38. Lerner A, Case JD, Takahashi Y, et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc. 1958;80:2857-2860.
39. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336: 186-195.
40. Slominski A, Pruski D. Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. Exp Cell Res. 1993;206:189-194.
41. Slominski A, Chassalerris N, Mazurkiewicz J, et al. Murine skin as a target for melatonin bioregulation. Exp Dermatol. 1994;3:45-50.
42. Slominski A, Baker J, Rosano T, et al. Metabolism of serotonin to N-acetylserotonin, melatonin and 5-hydroxytryptamine in hamster skin culture. J Biol Chem. 1996;271:12281-12286.
43. Slominski A, Paus R, Bomirski A. Hypothesis: a possible role of the melatonin receptor in vitiligo. J R Soc Med. 1989;82: 539-541.
44. Slominski A, Wortsman J, Mazurkiewicz J, et al. Detection of the proopiomelanocortin derived-antigens in normal and pathologic human skin. J Lab Clin Med. 1993;122:658-666.
45. Slominski A. POMC gene expression in mouse and hamster melanoma cells. FEBS Lett. 1991;291:165-168.
46. Schauer E, Trautinger F, Kock A, et al. Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest. 1994;93:2258-2262.
47. Slominski A, Ermak G, Hwang J, et al. Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. FEBS Lett. 1995;374:113-116.
48. Slominski A, Baker J, Ermak G, et al. UVB stimulates production of corticotropin releasing factor (CRF) by human melanocytes. FEBS Lett. 1996;399:175-176.
49. Slominski A, Mihm M. On a potential mechanism of skin response to stress. Int J Dermatol. 1996;35:849-851.
50. Wintzen M, Gilchrest BA. Proopiomelanocortin, its derived peptides, and the skin. J Invest Dermatol. 1996;106:3-10.
51. Autelitano DJ, Lundblad JR, Blum M, et al. Hormonal regulation of POMC gene expression. Annu Rev Physiol. 1989;51:715-726.
52. Smith AI, Funder JE. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocr Rev. 1988;9:159-179.
53. Slominski A, Ermak G, Mihm M. ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. J Clin Endocrinol Metab. 1996;81:2746-2749.
54. Ghanem G, Lienrad D, Hanson P, et al. Increased serum alpha-melanocyte stimulating hormone (alpha-MSH) in human malignant melanoma. Eur J Cancer Clin Oncol. 1986;22:535-536.
55. Loir B, Bouchard B, Morandini R, et al. Immunoreactive α-melanotropin as an autocrine effector in human melanoma cells. Eur J Biochem. 1997;244:923-930.
56. Siegrist W, Eberle AN. Melanocortins and their implication in melanoma. Trends Endocrinol Metab. 1995;6:115-120.
57. Hunt G. Melanocyte-stimulating hormone: a regulator of human melanocyte physiology. Pathobiology. 1995;63:12-21.
58. Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet. 1996;5:1663-1666.
59. Luger TA, Scholzen T, Brzoska T, et al. Cutaneous immunomodulation and coordination of skin stress responses by alpha-melanocyte-stimulating hormone. Ann N Y Acad Sci. 1998. In press.
60. Schmidt B, Weinberg DS, Hollister K, et al. Analysis of melanocytic lesions by DNA image cytometry. Cancer. 1994;73:2971-2977.
61. Karlsson M, Boeryd B, Carstensen J, et al. DNA ploidy and S-phase fraction in primary melanomas and their regional metastases. Melanoma Res. 1994;4:47-51.
62. Bjornhajen V, Auer G, Lagerlof B, et al. DNA analysis in archival material from primary malignant melanoma. Anal Quant Histol Cytol. 1991;13:335-342.
63. Karlsson M, Jungnelius U, Aamdal S, et al. Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated melanoma. Int J Cancer. 1996;65:1-5.
64. Parmiter RH, Nowell PC. Cytogenetics of melanocytic tumors. J Invest Dermatol. 1993;100:254S-258S.
65. Heim S, Mitelman F. Cancer Cytogenetics. New York, NY: Wiley-Liss; 1995.
66. INK4b genes as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 1996;56: 5023-5032.
67. Holland EA, Beaton SC, Edwards BG, et al. Loss of heterozygosity and homozygous deletions on 9q21-22 in melanoma. Oncogene. 1994;9:1361-1365.
68. Su YA, Trent JM. Genetics of cutaneous malignant melanoma. Cancer Control. 1995;2:392-397.
69. Thompson FH, Emerson J, Olson S, et al. Cytogenetics in 158 patients with regional or disseminated melanoma: subset analysis of near-diploid and simple karyotype. Cytogenet Cell Genet. 1995;83:93-104.
70. Robertson G, Coleman A, Lugo TG. A malignant melanoma tumor suppressor on human chromosome 11. Cancer Res. 1996;56:4487-4492.
71. Dracopoli NC, Houghton AN, Old LJ. Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Nad Acad Sci U S A. 1985;82: 1470-1474.
72. Fountain JW, Bale SJ, Housman DE, et al. Genetics of melanoma. Cancer Surv. 1990;9:645-671.
73. Millikin D, Meese E, Vogelstein B, et al. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res. 1991;51:5449-5453.
74. Walker GJ, Palmer JM, Walters MK, et al. Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int J Cancer. 1994;58:203-206.
75. Robertson GP, Coleman AB, Lugo TG. Mechanisms of human melanoma cell growth and tumor suppression by chromosome 6. Cancer Res. 1996;56:1635-1641.
76. Trent JM, Stanbridge EJ, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science. 1990;247:568-571.
77. Ray ME, Su YA, Meltzer PS, et al. Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma. Oncogene. 1996;12:2527-2533.
78. INK4 (CDKN2) gene in familial melanoma. Melanoma Res. 1996;6:139-145.
79. ARF. Cell. 1997;91:555-558.
80. Borg A, Johansson U, Hakansson O, et al. Novel germline p16 mutation in familial melanoma in southern Sweden. Cancer Res. 1996;56:2497-2500.
81. INK4 gene) during tumors progression in sporadic melanoma patients. Cancer Res. 1995;55:5531-5535.
82. Ohta M, Berd D, Shimizu M, et al. Deletion mapping of chromosome region 9p21p22 surrounding the CDKN2 locus in melanoma. Int J Cancer. 1996;65:762-767.
83. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
84. Holland EA, Beaton SC, Becker TM, et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene. 1995;11:2289-2294-
85. ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996;93:8541-8545.
86. Wang Y, Becker D. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system. Oncogene. 1996;12:1069-1075.
87. Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995;55:2713-2718.
88. Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res. 1994;54:5269-5272.
89. Gordon KB, Thompson CT, Char DH, et al. Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res. 1994;54: 4764-4768.
90. Wiltshire RN, Duray P, Bittner ML, et al. Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res. 1995;55:3954-3957.
91. Harris CC. P53: at the crossroads of molecular carcinogenesis and molecular epidemiology. J Invest Dermatol Symp Proc. 1996;1:115-118.
92. Bae I, Smith ML, Sheikh MS, et al. An abnormality in the p53 pathway following γ-irradiation in many wild-type p53 human melanoma lines. Cancer Res. 1996;56:840-847.
93. Davol PA, Goulette FA, Frackelton AR, et al. Modulation of p53 expression by human recombinant interferon-α2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Cancer Res. 1996;56: 2522-2526.
94. INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12:97-99.
95. INK4 proteins in cutaneous malignant melanoma. Br J Dermatol. 1996;134:269-275.
96. Degen WGJ, Weterman AAJ, VanGroningen JJM, et al. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts. Int J Cancer. 1996;65:460-465.
97. Easty DJ, Maung K, Lascu I, et al. Expression of NM23 in human melanoma progression and metastasis. Br J Cancer. 1996;74:109-114.
98. Isshiki K, Elder DE, Guerry D, et al. Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer. 1993: 8:178-184.
99. Yamanishi DT, Buckmeier JA, Meyskens FL. Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas. J Intest Dermatol 1991;97:349-353.
100. Manova K, Bachvarova RE Expression of c-kit encoded at the W locus of mice in developing embryonic germ cells and presumptive melanoblasts. Dev Biol. 1991;146:312-324.
101. Kirsch KH, Korradi Y, Johnson JP. Mader: a novel nuclear protein over expressed in human melanomas. Oncogene. 1996;12:963-971.
102. Adema GJ, deBoer AJ, van't Hullenaar R, et al. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 1993;143:1579-1585.
103. Wagner SN, Wagner C, Hofler FH, et al. Expression cloning of the cDNA encoding a melanoma-associated Ag recognized by mAb HMB-45: identification as melanocyte-specific Pmell7 cDNA. Lab Invest. 1995;73:229-235.
104. Chakraborty AK, Platt JL, Kwon BS, et al. Polymerization of 5,6-dihydroxyindole 2-carboxylic acid to melanin by the PMEL17/silver locus. Eur J Biochem. 1996;236:180-188.
105. Kobayashi T, Urabe K, Winder A, et al. Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J. 1994;13:5818-5825.
106. Tsukamato K, Jackson IJ, Urabe K, et al. A second tyrosinase-related protein, TRP2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J. 1992;11:519-526.
107. Yokoyama K, Yasumoto KI, Suzuki H, et al. Cloning of the human DOPAchrome tautomerase/tyrosinase-related protein 2 gene and identification of two regulatory regions required for its pigment cell-specific expression. J Biol Chem. 1994; 269:27080-27087.
108. DelMarmol V, Beermann F. Tyrosinase and related proteins in mammalian pigmentation. FEBS Lett. 1996;381:165-168.
109. Komer AM, Pawelek JM. Mammalian tyrosinase catalyzed three reactions in the biosynthesis of melanin. Science. 1982;217:1163-1165.
110. Slominski A, Moellmann G, Kuklinska E. L-tyrosine, L-dopa and tyrosinase as positive regulators of the subcellular apparatus of melanogenesis in Bomirski Ab amelanotic melanoma. Pigment Cell Res. 1989;2:109-116.
111. Slominski A, Paus R. Towards defining receptors for L-tyrosine and L-DOPA. Mol Cell Endocrinol. 1994;99:C7-C11.
112. Slominski A, Paus R. Are L-tyrosine and L-dopa hormone-like bioregulators. J Theor Biol. 1990;143:123-138.
113. Sonesson B, Elde S, Ringborg U, et al. Tyrosinase activity in the serum of patients with malignant melanoma. Melanoma Res. 1995;5:113-116.
114. Kageshita T, Wang Z, Calorini L, et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res. 1993;53:3349-3354.
115. Stene MA, Babajanians M, Bhuta S, et al. Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol. 1988;91:125-128.
116. Nabel GJ, Gordon D, Biship DK, et al. Immune response in human melanoma after transfer of an allogeneic class 1 major histocompatibility complex gene with DNA-liposome complexes Proc Natl Acad Sci U S A. 1996;93:15388-15393.
117. Livingston PO, Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer, 2: previous experience and future plans. Cancer Immunol Immunother. 1997;45:10-19.
118. Ravindranath MH, Morton DL. Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines. Cancer Invest. 1997;15:491-499.
119. Schadendorf D. Cytokines, autologous cell immunostimulatory, and gene therapy for cancer treatment. In: Bos JD, ed. The Skin Immune System. Boca Raton, Fla: CRC Press; 1997:657-659.
120. Kageshita T, Nakamura T, Yamada M, et al. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res. 1991;51:1726-1732.
121. Kageshita T, Kuriya N, Ono T, et al. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res. 1993;53:2830-2833.
122. Clark WH Jr, Elder DE, Guerry DP IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
123. De Vries TJ, Quax PHA, Denijn M, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol. 1994;144:70-51.
124. Debaldo C, Masouye I, Saurat JH, et al. Plasminogen activation in melanocytic neoplasia. Cancer Res. 1994;54:4547-4552.
125. Johnson JP, Lehmann JM, Stade BG, et al. Functional aspects of three molecules associated with metastasis development in human malignant melanoma. Invasion Metastasis. 1989;9: 338-350.
126. Kageshita T, Yoshii A, Kimura T, et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res. 1993;53:4927-4932.
127. Schadendorf D, Gawlik C, Haney U, et al. Tumor progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol. 1993;170:429-434.
128. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variance expressing high and low levels of CD44. Cancer Res. 1991;51:6660-6667.
129. Wibe E, Hannisdal E, Paus E, et al. Neuron-specific enolase as a prognostic factor in metastatic melanoma. Eur J Cancer. 1992;28A:1692-1695.
130. Jimbow K, Lee SK, King MG, et al. Melanin pigments and melanosomal proteins as differentiation markers unique to normal and neoplastic melanocytes. J Invest Dermatol. 1993;100:259S-268S.
131. Rorsman H, Agrup G, Hansson C, et al. Biochemical recorders of malignant melanoma. In: MacKie RM, ed. Pigment Cell. Basel: Karger, 1983;6:93-115.
132. Hara H, Walsh N, Yamada K, et al. High plasma levels of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma. J Invest Dermatol. 1994;102:501-505.
133. Horikoshi T, Ito S, Wakamatsu K, et al. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer. 1994;73:629-636.
134. Brossart P, Keilholz U, Willhauck M, et al. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol. 1993;101:887-889.
135. Slominski A, Goodman-Snitkoff G. DOPA inhibits induced proliferative activity of murine and human lymphocytes. Anticancer Res. 1992;12:753-756.
136. Slominski A, Paus R. Inhibition of melanogenesis for melanoma therapy? J Invest Dermatol. 1995;103:742. Letter.